What is Omidria patent 2911511 (and what does it cover)?
Patent number 2911511 is a U.S. patent associated with the branded ophthalmic/ophthalmology-related product Omidria (marketed in the U.S. as a medication used during cataract surgery). Patent coverage details depend on the specific claim set and filing family, but the usual way to interpret “Omidria patent 2911511” in search results is to identify what the patent claims protect (for example, the specific drug formulation, method of use, or related dosing/administration).
To determine exactly what #2911511 covers, you need to look up the patent record and read the “Claims” section and any “Abstract”/“Description” summary. (The patent number alone usually isn’t enough to state precise claim scope without pulling the actual text.)
When does Omidria patent 2911511 expire?
Patent expiry depends on the patent’s filing date, whether there are patent-term adjustments, and whether any extensions apply. In the U.S., patents generally expire 20 years from the earliest effective filing date (with possible adjustments), but the exact date for a specific patent must be read from the patent’s maintenance/expiration information on the official patent record or a patent database.
Is patent 2911511 the one that matters for generic or biosimilar competition?
For branded drugs like Omidria’s active ingredients, the relevant “exclusivity” story can involve multiple layers:
- patent protection tied to specific claims, and
- regulatory exclusivity and approvals (for example, whether a generic can enter based on a Paragraph IV certification or whether other exclusivity periods apply).
So users searching a single patent number often want to know whether that patent is listed in the regulatory patent listings for the product and whether it blocks generic entry. That requires cross-checking the patent against the applicable regulatory listing for Omidria and any related patent families.
Where can I verify Omidria patent 2911511 details?
The fastest way to confirm scope and key dates is to look it up in:
- the USPTO patent document for number 2911511, and
- a regulatory patent listing source used for drug competition (commonly referenced in FDA Orange Book contexts, where applicable).
What should I check in the patent to understand the risk or scope?
When people ask about a specific drug patent number, they typically want practical answers that come from the record:
- the independent claims (what is actually protected),
- the active ingredient/formulation and route/dosing language in the claims,
- any method-of-use limitations,
- whether the claims are tied to a particular surgical setting (the Omidria use case),
- whether the patent is still in force (maintenance fees paid) or has lapsed.
Do you mean a different patent number?
“2911511” is a long numeric string, and patent identifiers can be easy to mistype. If you can share the country/office (U.S. patent vs. another jurisdiction) or a link/screenshot of where you saw “2911511,” I can help interpret the exact patent record you mean and what it protects (claims) and when it expires.
Sources
I don’t have the underlying patent text or official record for “Omidria patent 2911511” in the information provided here, so I can’t cite or confirm claim scope or expiration dates without the actual patent document. If you paste the link to the USPTO/Google Patents record for that number, I can summarize the claims and timeline precisely.